WilmerHale Successfully Represents Fabre-Kramer Pharmaceuticals in Collaboration with GlaxoSmithKline

WilmerHale Successfully Represents Fabre-Kramer Pharmaceuticals in Collaboration with GlaxoSmithKline

Client News

Related Solutions

We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

WilmerHale successfully represented its client Fabre-Kramer Pharmaceuticals in its worldwide development and commercialization agreement with GlaxoSmithKline for Fabre-Kramer's gepirone ER product, a 5HT1a agonist expected to be submitted in the first quarter of 2007 for FDA review in the US for major depressive disorder (MDD). Under the terms of the agreement, Fabre-Kramer Pharmaceuticals will receive an upfront cash payment followed by additional development and commercialization milestone payments and double-digit percentage royalty payments on worldwide sales of gepirone ER and follow-on products. In return, GlaxoSmithKline was granted an exclusive, worldwide license to develop, manufacture and commercialize gepirone ER and follow-on products.

The WilmerHale lawyers working on the transaction included David Redlick, Steven Barrett, Allison May and James Czaban.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel